University of Southern California

Gaffney, Kevin J.

Rodgers, Kathleen, E.

Louie, Stan G.

Petasis, Nicos A.

Dizerega, Gere, S.

Stan G Louie

Nicos A Petasis

Kathleen Elizabeth Rodgers

Gere S DiZerega

Kevin J Gaffney

Florence M Hofman

Mark Salman Humayun

Thomas C Chen

Axel H Schonthal

Mark S Humayun

Thonas C Chen

Axel H Schönthal

Eve Kelland

Brett Lund

Walid Fouad Ahmed Abdallah

Gere S Dizerega

This invention provides compounds, methods and compositions for the treatment of ophthalmic diseases and disorders, including retinal and choroidal disorders and related conditions. More particularly, the invention provides a method of using the provided pharmaceutical compositions for the treatment of ophthalmic diseases and disorders, including retinal and choroidal diseases, and related conditions, upon topical administration to the eye.

Methods and compositions for the treatment of ophalmic diseases and disorders

Disclosed herein are compositions including cyclodextrin and Nle3-A(1-7) [Asp-Arg-Me-Tyr-Ile-His-Pro (SEQ ID NO: 1)] and their use in treating various disorders.

Cyclodextrin-Nle3-A(1-7) compositions and their use

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases.

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

This invention provides methods, compounds and compositions for the treatment of musculoskeletal disease, muscle dysfunction, muscle-wasting disease or disorder, including hereditary myopathy, neuromuscular disease, muscular dystrophy, muscular atrophy, drug-induced myopathy, and related disease, disorder or condition that causes a decrease in muscle strength, comprising the use of heterocyclic non-peptidic compounds that act as Mas agonists and/or mimics of angiotensin 1-7.

Methods, compounds, and compositions for the treatment of musculoskeletal diseases

Disclosed herein are methods for treating eye injuries by administering one or more angiotensin peptides to a subject with an eye injury.

Accelerated healing of eye injuries by angiotensin peptides

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.

The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.

Methods for treating multiple sclerosis

The present invention provides a method for inducing apoptosis in selected cells by aggravating ER-stress. The aggravation of ER-stress is achieved in a specific manner by inhibiting SERCA (sarcoplasmic/endoplasmic reticulum calcium ATPase), leading to elevated level of cytoplasmic calcium concentration, yet without inhibiting the activity of COX-2 (cyclooxygenase-2) or triggering the release of histamine. Induction of apoptosis may be enhanced by first inducing or further aggravating ER-stress through inhibition of proteasome or proteases. Also provided are compounds and compositions useful as ER-stress aggravating agents, methods for screening, selecting, identifying and designing the same and methods for treating diseased conditions by inducing apoptosis through specific and selective aggravation of ER-stress.

Growing community of inventors

Fullerton, CA, United States of America

Stan G Louie